Gemogenovatucel-T

Drug Overview

Gemogenovatucel-T represents a cutting-edge shift in cancer care. It is a personalized Immunotherapy often referred to as a “cancer vaccine.” Unlike standard medications that are the same for everyone, this drug is a “living medicine” created specifically for each individual patient using their own tumor cells.

In the medical world, this is known as a Targeted Therapy because it trains the body’s own immune system to find and destroy very specific cancer “targets.” It is currently one of the most promising research areas for patients with advanced gynecological cancers, offering a personalized approach when other treatments may have failed.

• Generic Name: Gemogenovatucel-T (also known as Vigil)
• US Brand Names: Vigil
• Drug Class: Autologous Tumor Cell Vaccine; Gene-mediated Immunotherapy
• Route of Administration: Intradermal (Injection into the skin)
• FDA Approval Status: Investigational (Fast Track and Orphan Drug designations granted)

What Is It and How Does It Work? (Mechanism of Action)

To understand how gemogenovatucel-T works, imagine your immune system is a security team that has “fallen asleep” because cancer cells have learned to wear a cloaking device. This drug acts like a high-tech training program that wakes up the security team and shows them exactly what the cancer looks like.

At the molecular level, the process is highly sophisticated:

1. Personalized Manufacturing: Doctors take a sample of the patient’s actual tumor during surgery. In a lab, scientists insert a specific piece of DNA (a plasmid) into these tumor cells.
2. Blocking the “Cloak”: Cancer cells produce a protein called TGF-beta, which acts like a chemical shield that paralyzes the immune system. The inserted DNA contains “shRNA” (short hairpin RNA) that specifically blocks the production of this shield.
3. The “Dinner Bell” (GM-CSF): The DNA also tells the tumor cells to produce GM-CSF. This protein acts like a chemical dinner bell, calling immune cells (dendritic cells) to the injection site.
4. The Training Session: Because the “shield” is gone and the “dinner bell” is ringing, the immune system finally sees the tumor’s unique markers (antigens). It then “trains” specialized T-cells to go out and hunt any cell in the body that carries those exact markers.

FDA Approved Clinical Indications

As an investigational drug, gemogenovatucel-T is primarily available through clinical trials or expanded access programs.

Oncological Uses (Investigological)

• Ovarian Cancer: Maintenance therapy for patients with advanced-stage, high-grade serous ovarian cancer.
• Ewing Sarcoma: For patients with this rare bone and soft tissue cancer that has returned or spread.
• Other Solid Tumors: Being studied for various cancers that do not respond to standard care.

Non-Oncological Uses

• None. This therapy is strictly designed for the treatment of malignant tumors.

Dosage and Administration Protocols

Gemogenovatucel-T is administered in a cycles, usually following a specific schedule determined by the oncology team.

Special Adjustments:

• Renal/Hepatic Insufficiency: Because this is a cell-based therapy and not a chemical drug, it is not processed by the liver or kidneys in the same way. Therefore, standard dose adjustments for these conditions are usually not required.

Clinical Efficacy and Research Results

Clinical data from 2020 to 2025 has shown significant potential for gemogenovatucel-T to prevent cancer from coming back (recurrence).

• VITAL Trial (Ovarian Cancer): In patients with a specific genetic profile (BRCA-wild type), the drug significantly extended Relapse-Free Survival. Numerical data suggests that the risk of the cancer returning was reduced by nearly 50% in this specific group.
• Overall Survival: Long-term follow-up data has shown that patients receiving this personalized vaccine lived significantly longer than those receiving a placebo or standard observation.
• Ewing Sarcoma: Early research shows a “Disease Control Rate” of over 70% in patients whose cancer had previously stopped responding to chemotherapy.

Safety Profile and Side Effects

Because gemogenovatucel-T uses the patient’s own cells and focuses on the immune system, it is generally much “gentler” than chemotherapy.

Black Box Warning:

None. As an investigational immunotherapy, it does not currently have an FDA Black Box Warning.

Common Side Effects (>10%)

• Injection Site Reaction: Redness, swelling, or itching where the needle went in.
• Fatigue: Feeling unusually tired or weak.
• Flu-like Symptoms: Mild fever or chills (a sign the immune system is “waking up”).

Serious Adverse Events

• Severe Allergic Reaction: Rare but possible during any injection.
• Immune-Related Inflammation: A rare condition where the immune system becomes overactive and attacks healthy tissue.

Management Strategies

• For Injection Pain: Use a cold compress on the area.
• For Fatigue: Plan for rest on the day of and the day after your injection.

Connection to Stem Cell and Regenerative Medicine

Research Areas: Gemogenovatucel-T is a pioneer in the field of “Living Medicine,” which overlaps heavily with Regenerative Medicine. Current research is exploring how to combine this tumor-cell vaccine with Stem Cell-derived Immunotherapy. Scientists are investigating if stem cells can be used to “boost” the number of T-cells the vaccine produces. This combination could potentially create an “immune memory” that protects the patient from cancer for the rest of their lives.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Tumor Biopsy/Surgery: A fresh sample of your tumor is required to create the drug.
• Genetic Profiling: Testing for BRCA mutations is often done to see if you are in the group most likely to benefit.

Precautions During Treatment

• Injection Site Care: Do not apply lotions or creams to the injection site for 24 hours.
• Consistency: Maintenance therapy works best when you do not skip your monthly doses.

“Do’s and Don’ts” List

• Do stay hydrated and rest if you feel “flu-like” after your dose.
• Do inform your doctor of any new medications, as some can suppress the immune system.
• Don’t be alarmed by a small “bump” at the injection site; this is usually a sign the vaccine is working.
• Don’t receive other vaccines (like the flu shot) within 2 weeks of your treatment without asking your oncologist.

Legal Disclaimer

Standard Medical Information Disclaimer: This guide is for informational purposes only and does not constitute medical advice. Gemogenovatucel-T (Vigil) is an investigational drug and is currently only available through clinical trials. Always consult with a licensed oncologist or healthcare professional to discuss treatment options, risks, and benefits specific to your medical history. This content reflects data available as of 2026.